Key Takeaways Denali posted a Q3 loss of $0.74 per share, wider than last year's $0.63 loss. FDA extended tividenofusp alfa's approval decision to April 2026 after a major amendment.DNLI advanced programs for Sanfilippo, Alzheimer, Parkinson and Pompe diseases.Denali Therapeutics (DNLI) reported a third-quarter 2025 loss of 74 cents per share, narrower than the Zacks Consensus Estimate of a loss of 76 cents. The company reported a loss of 63 cents in the year-ago quarter.The loss per share widened year over ...